REGISTER BY DECEMBER 8 TO SAVE $500

4th Annual

ICI Boston

March 19-21, 2018
Boston, MA
www.immune-checkpoint.com

- **Identify Clinically Effective Combinations**
- **Leverage the Holistic Tumor Microenvironment**
- **Validate Patient Selection Biomarkers**

30 Expert Speakers Including:

Roger Dansey
SVP, Global Clinical Development Oncology
Merck

Bernard Fox
Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology,
Providence Cancer Center

Bill Grossman
Group Medical Director, Cancer Immunotherapy
Genentech

Israel Lowy
VP, Clinical Sciences & Head of Translational Oncology
Regeneron

Lata Jayaraman
Head of Tumor Immunotherapy
Seres Therapeutics

Amy Peterson
CMO, Immuno-Oncology
BeiGene

Corinne Reimer
Associate Director, In Vivo Pharmacology
AstraZeneca

Catherine Sabatos-Peyton
Director
Novartis

Jochem Gokemeijer
Associate Director, Molecular Discovery Technologies
Bristol-Myers Squibb

"This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics!" AstraZeneca

Partners To Date:

MITRA BIOTECH™ IMMUDEX

hansonwade

Tel: +1 212 537 5898 **Email:** info@hansonwade.com
@ici_checkpoint Immune Checkpoint Inhibitors

Granular Insights to Enhance the Success of Your IO Pipeline

Returning for the 4th time, ICI Boston is the definitive forum focused exclusively on how to deliver maximum clinical benefit through immune checkpoint modulation.

Rather than attempting to cover the entire IO space and only providing superficial insights, this conference has the focus required to drill down into the real details. Discover how to overcome key preclinical, translational and clinical drug development challenges encountered in the development of checkpoint modulators.

ICI Boston will unite industry leaders including Merck, BMS, Genentech and Novartis to share in-depth case studies on topics such as **overcoming resistance** to checkpoint blockade, **identifying translational biomarkers** and **understanding the mechanistic rationale behind combination strategies.**

Join leading drug developers who have successfully developed IO therapeutics and ensure you make the right decisions with your IO pipeline.

HEAR WHAT PREVIOUS ATTENDEES HAVE TO SAY:

"Excellent meeting. Great opportunity for discussions between large pharma, small start ups, academia and regulatory authorities"
Merck

"It was a great conference, great selection of topics and speakers"
Berg Pharma

"This conference represents a great opportunity for sharing the latest science, networking and establishing new collaborations"
Boehringer Ingelheim

An Unparalleled Depth of Insights

1.

A Comprehensive Breakdown of the Factors that Influence Combination Efficacy
Understand the role that sequence, dosing, trial design and treatment duration play in combination studies, enabling you to refine your combination strategy to maximize the likelihood of success

2.

Mechanistic Insights into the Role of the Tumor Microenvironment
Learn how to analyze and leverage a diverse array of cell types in the TME, including an in-depth analysis of cross-talk with the microbiome, to unleash a more potent and holistic anti-tumor immune response

3.

In-Depth Case Studies Outlining the Identification of Translational Biomarkers
Stratify and select patients for IO clinical trials more effectively by gaining a deep understanding of the target and biomarker biology in the context of the MoA of immune checkpoint modulators and combinations

4.

Examining the Latest Preclinical Modelling Approaches
Enter the clinic with a more robust and validated approach by understanding how you can leverage cutting edge preclinical technologies with the capability of recapitulating the tumor microenvironment more effectively than ever before

5.

Sharing the Scientific Rational Behind Targeting Novel Checkpoint Pathways
Discover the true value of pathways such as LAG-3, TIM-3, ICOS and CD73 and to exploit these pathways most effectively through monotherapy and combination studies

30+ Expert Speakers

Michal Bassani-Sternberg
Director, Immunopeptidomics Unit at Center of Experimental Therapeutics
UNIL/CHUV

Yan Lan
Senior Director, Translational Immunology
EMD Serono

Scott Bultman
Associate Professor, Genetics
UNC School of Medicine

Jennifer Cochran
Co-Founder and Director
Nodus Therapeutics
and Associate Professor and Department Chair Bioengineering
Stanford University

Roger Dansey
SVP, Global Clinical Development Oncology
Merck

Bernard Fox
Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology
Providence Cancer Center

Jochem Gokemeijer
Associate Director, Molecular Discovery Technologies
Bristol-Myers Squibb

Bill Grossman
Group Medical Director, Cancer Immunotherapy
Genentech

Jeffrey Hanke
CSO & EVP, Research & Development
Tesaro

Lata Jayaraman
Head of Tumor Immunotherapy
Seres Therapeutics

Barbara Joyce-Shaikh
Associate Principal Scientist
Merck

Israel Lowy
VP, Clinical Sciences & Head of Translational Oncology
Regeneron

Jason Luke
Assistant Professor of Medicine
University of Chicago

Jennifer Mataraza
Senior Investigator II, Group Leader, Translational Immuno-Oncology
Novartis

David McDermott
Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center

Shuji Ogino
Professor & Chief of Program in MPE Molecular Pathological Epidemiology
Dana-Farber Cancer Institute

Mark Paris
Assistant Director, Translational Applications
Mitra Biotech

Amy Peterson
CMO, Immuno-Oncology
BeiGene

Rodney Prell
Principal Scientist, Toxicologist & Cancer Immunotherapy Area Lead
Genentech

Osama Rahma
Assistant Professor of Medicine
Dana-Farber Cancer Institute

Corinne Reimer
Associate Director, In Vivo Pharmacology
AstraZeneca

Bonnie Rup
Biopharmaceutical Consultant
Bonnie Rup Consulting

Catherine Sabatos-Peyton
Director
Novartis

Tim Sullivan
VP, Business Development
Arcus Biosciences

Anna Tafuri
Global Early Clinical Lead
Bayer

Beth Trehu
CMO
Jounce

Shannon Turley
Principal Scientist, Cancer Immunology
Genentech

Chris Turner
VP, Clinical Science
Celldex Therapeutics

Bob Uger
CSO
Trillium Therapeutics

Jianda Yuan
Director, Translational Immuno-Oncology Research & Early Clinical Development
Merck

"The speakers truly love what they do and it resonated in their presentations"
Regeneron

Day One | Tuesday, March 20

Bernard Fox
Providence Cancer Center

8.20 Chair's Opening Remarks

Pioneering Rational Combination Approaches

Roger Dansey
SVP, Global Clinical Development Oncology
Merck

8.30 Keynote: Enhancing Patient Outcomes with Pembrolizumab in Combination Strategies

- Investigating diverse combination strategies with pembrolizumab
- Critical considerations for developing effective combination strategies – improving outcomes and maintaining tolerability
- Understanding clinical combinations: biologic rationale and expecting the unexpected

Bill Grossman
Group Medical Director, Cancer Immunotherapy
Genentech

9.00 Keynote: Addressing the Tidal Wave of Cancer Immunotherapy Combinations Through Innovative Trial Designs

- Highlighting the opportunity for novel clinical trial designs to address developmental challenges in the cancer immunotherapy space
- Understanding key clinical development challenges for cancer immunotherapy combination development
- Developing a combination platform to increase the speed of identification of transformative signals
- Examples of novel clinical trial designs to address combination development challenges

9.30 Speed Networking & Morning Refreshments

PRECLINICAL TRACK

Identifying Translationally Relevant Biomarkers

11.00 Transforming Translational Research: CANscript™ - A Better Predictive Model For Oncology

- Developing and clinically validating a fully human ex-vivo platform technology (CANscript™)
- Using patient material (tumor, autologous ligands and PBMC) to explore the mechanism of action and predict efficacy for clinically-directed compounds in a modality-agnostic way using phenotypic effects
- Explore how CANscript was used to model the effect of checkpoint inhibition in HNSCC as a means of identifying predictors of clinical response and uncovering mechanisms of resistance

Mark Paris, Associate Director, Translational Applications, **Mitra Biotech**

11.30 From Bench to Clinic: Developing Biomarker Strategies for Immunotherapy Combinations

- Using a deep understanding of target biology to narrow the list of candidate biomarkers that relate to the mechanism of action of a given drug
- Challenges in interpreting biomarker data from combination studies

Jennifer Mataraza, Senior Investigator II, Group Leader, Translational Immuno-Oncology, **Novartis**

CLINICAL TRACK

Achieving Preclinical & Clinical Success Through Rational Combinations

11.00 Investigating Mechanisms of Resistance to Checkpoint Modulator Monotherapies & Combinations

- Assessing our understanding of mechanisms of resistance and how patients develop resistance to checkpoint modulators
- Investigating potential causes of long-term resistance
- Evaluating how rational combination approaches can overcome resistance

Osama Rahma, Assistant Professor, **Dana-Farber Cancer Institute**

11.30 Investigating the Potential of TIM-3 & LAG-3 in the Context of Novel Combination Strategies

- Understanding how substantial numbers of patients in all tumor types do not respond to anti-PD1/L1 therapy, and patients eventually progress on therapy, suggesting other mechanisms of immune escape persist across tumors
- Learning about theLAG-3 and TIM-3 agents that are in development to address de novo refractory tumors and treatment emergent resistance
- Providing an update on role of LAG-3 and TIM-3 in tumors and status of TSR-033 (anti-LAG3) and TSR-22 (anti-TIM3)

Jeffrey Hanke, CSO & EVP, Research & Development, **TESARO**

12.00 Pharmacodynamic & Predictive Biomarkers in Clinical Development of JTX-2011, an ICOS Agonist

- Identifying two important biomarkers for clinical development through preclinical efficacy studies
- Using a pharmacodynamic biomarker in Phase 1 to identify the recommended Phase 2 dose
- Selecting indications and enriching patient enrolment in Phase 2 using a potential predictive biomarker

Beth Trehu, CMO, **Jounce**

12.00 Rational IO/IO & IO/ADC Combinations to Modulate the Immune System

- Using the CD27 agonist antibody, Varlilumab, in combination with anti-PD1 antibody, Nivolumab, in advanced cancer patients
- Rationale, preclinical and early clinical data combining the anti-gpNMB ADC Glembatumumab Vedotin with immunotherapy
- Rationale and preclinical data for using a CD40 agonist antibody in IO combinations

Chris Turner, VP, Clinical Science, **Celldex**

12.30 Lunch & Networking

'Extreme Personalized Medicine' – The Future of Immuno-Oncology?

2.00 Beyond PD-L1: Understanding Novel Translational Biomarkers to Stratify Patients Effectively for Personalized Cancer Immunotherapy

- Analyzing patient level biomarker stratification approaches to compare novel immunotherapy combinations more accurately
- Combining new omics technologies to give a comprehensive picture of the tumor microenvironment to guide immunotherapy applications
- Evaluating large data sets to discover gene signatures that will enhance the predictability of clinical outcomes

Jianda Yuan, Director, Translational Immuno-Oncology Research, **Merck**

2.30 Personalizing Immunotherapy by Analysing the Role of Environmental and Microbial Factors

- Broadening the scope – understanding environmental and microbial factors that affect patient responses to immunotherapy
- Analyzing human samples to investigate the influence of exosome and microbiome on immune responses
- Examining factors like microsatellite instability and neoantigen load that affect immunotherapy outcomes

Shuji Ogino, Professor, **Dana-Farber Cancer Institute**

Driving Novel Combination Approaches Into The Clinic

2.00 Innate & Adaptive Integrin-Targeted Combination Immunotherapy

- Developing an engineered integrin-binding peptide-Fc fusion that targets and recruits immune cell effector functions to tumors
- Invoking innate and adaptive arms of the immune system through the co-administration of the peptide-Fc fusion and an immune modulator, such as a checkpoint blockade inhibitor, results in significant control of tumor growth

Jennifer Cochran, Co-Founder and Director, **Nodus Therapeutics** and Associate Professor, Bioengineering & Chemical Engineering, **Stanford University**

2.30 Targeted Alpha Irradiation: A New Partner for Immunotherapy?

- Targeted alpha therapy : clinical features and potential challenges
- Targeted alpha irradiation as a novel approach for Mesothelin-expressing tumors
- Clinical approach targeting CD22

Anna Tafuri, Global Early Clinical Lead, **Bayer**

3.00 Afternoon Refreshments & Poster Viewing

Turning Up the Heat on Cold Tumors by Engaging the Broader Tumor Microenvironment

Jason Luke
Assistant Professor of Medicine
University of Chicago

4.00 Tumor & Host Factors Influencing the Tumor Microenvironment & Response to Checkpoint Blockade

- Review the T cell-inflamed and non-T cell-inflamed tumor micro-environment as a model for predicting rational immunotherapy combinations
- Interrogate patient level gene expression profiling as a route to "personalized" combination immunotherapy
- Describe the impact of the commensal microbiome on anti-PD1 responsiveness in melanoma

Shannon Turley
Principal Scientist, Cancer Immunology
Genentech

4.30 Evaluating the Role of Stromal Cells & TGFβ Signalling in the Resistance to Atezolizumab

- Understanding the role of stromal cells in the tumor microenvironment and the effect of cross-talk with immune cells
- Analyzing factors correlating with resistance to atezolizumab and reverse-translating this information to provide meaningful preclinical insights
- Building tools to study mesenchymal cells and their impact on immuno-oncology across tumor types

Bernard Fox
Providence Cancer Center

5.00 Chair's Closing Remarks

Day Two | Wednesday, March 21

8.30 Registration & Networking

Bernard Fox
Providence Cancer Center

8.25 Chair's Opening Remarks

Bernard Fox
Member and Chief, Molecular and Tumor Immunology
Providence Cancer Center

8.30 Keynote: Investigating Crucial Factors That Determine the Success of Immune Checkpoint Combinations

- Understanding the importance of sequencing and timing in the administration of combination therapies to maximize efficacy
- Investigating the most effective approaches to identify truly translational biomarkers to identify patients for checkpoint monotherapy and combination trials
- Appreciating the true potential of immuno-oncology: what does the future hold for the field and how can we work most effectively to realize this potential?

Israel Lowy
VP, Clinical Sciences & Head of Translational Oncology
Regeneron

9.00 Keynote: Defining the Treatment Duration of Checkpoint Blockade

- Understanding the factors that have influenced the typical dosing plan for PD-1/PD-L1 blockade
- How can the duration of treatment administration be optimized and what does optimization actually mean?
- Criteria that need to be taken into account when discussing treatment duration in the context of current immunotherapies

9.30 Keynote Panel Discussion: Dissecting Recent Clinical Successes and Failures to Give Greater Clarity Moving Forward

- Assessing the relative contributions of the molecule, patient population and endpoint selection to final result
- Discussing the ways in which recent clinical results have impacted the field and how priorities and practices will change in the near future as a result
- How will the recent CAR-T approval impact on the use of checkpoint modulators?
- Understanding the latest monotherapy data and how this will impact the field

Catherine Sabatos-Peyton
Director
Novartis

Jianda Yuan
Director, Translational Immuno-Oncology Research
Merck

Jochem Gokemeijer
Associate Director, Molecular Discovery Technologies
Bristol-Myers Squibb

10.00 Morning Refreshments & Networking

PRECLINICAL TRACK

Bridging the Translational 'Valley of Death' Through Clinically Relevant Preclinical Models

11.00 Modelling the Holistic Tumor Microenvironment in Preclinical Models

- Understanding the potential of humanized and syngeneic models in recapitulating the tumor micro-environment
- Generating humanized systems to validate targets in the myeloid compartment
- Exploring approaches to analyze MDSCs in humanized PDx models

Corinne Reimer, Associate Director, In Vivo Pharmacology, **AstraZeneca**

CLINICAL TRACK

Understanding the Developmental Stories Behind Successful Clinical Candidates

11.00 BGB-A317, a Late Clinical Stage Anti-PD-1 Antibody with an Engineered Fc Domain

- BGB-A317 is a humanized IgG4 mAb with high affinity and binding specificity against PD-1
- BGB-A317 was specifically engineered to minimize binding to FcγR on macrophages, abrogating antibodydependent phagocytosis, a potential mechanism of T-cell clearance
- Over 600 patients, representing a variety of tumor types, have received monotherapy BGB-A317

Amy Peterson, CMO, Immuno-Oncology, **BeiGene**

11.30 Preclinical Approaches to Model the Mechanism of Action of IO Monotherapies and Combinations More Effectively

- Understanding the role of in vivo and in vitro systems in translating IO therapeutics more effectively
- Handling the unexpected: preclinical case studies detailing unpredictable outcomes
- Overcoming key challenges in modelling combination immunotherapies

Barbara Joyce-Shaikh, Associate Principal Scientist, **Merck**

11.30 Novel Immuno-Oncology Trial Designs to Improve Kidney Cancer Therapy

- Interrogating key IO trials that have defined this space – what can we learn from successes and failures?
- Highlighting approaches to improve the design of IO clinical trials
- Evaluating patient selection approaches
- Assessing and validating novel immunotherapy endpoints

David McDermott, Director, Biologic Therapy and Cutaneous Oncology Programs, **Beth Israel Deaconess Medical Center**

12.30 Lunch & Networking

T Cells and Beyond – Investigating the True Value of the 'Next Generation' of Checkpoint Modulators

1.00 The Role of TIM-3 in Myeloid Biology

- Reviewing how emerging data suggests a key role for TIM-3 expression on myeloid cells
- Investigating a key subset of TIM-3 expressing dendritic cells
- Understanding the part these targets play in the broader immune response and how they can be exploited most effectively through rational combination approaches

Catherine Sabatos-Peyton, Director, **Novartis**

1.30 Targeting the Adenosine Pathway to Unleash Potent Immune Responses in the Tumor Microenvironment

- Outlining the scientific rationale behind targeting the adenosine pathway
- Sharing key findings from the progression of A2R antagonist and anti-CD73 small molecule therapeutics
- Investigating potential combinations involving adenosine-targeting approaches

Tim Sullivan, VP, Business Development, **Arcus Biosciences**

Laying the Foundations for Robust and Safe Clinical Development

1.00 Immunogenicity Challenges & Considerations for I-O Therapies

- Understanding that all biologics have the potential to elicit an immune response
- Analyzing how the MOA of IO therapies complicate anti drug immunogenicity
- Exploring how preclinical immunogenicity strategies to can reduce clinical development risk for IO therapies

Jochem Gokemeijer, Associate Director, Molecular Discovery Technologies, **Bristol-Myers Squibb**

1.30 Relating Non-Clinical Safety Considerations for IO Therapeutics to the Clinic

- Non-clinical weight of evidence approaches to support combination clinical studies
- Understanding limitations of current non-clinical models for cancer immunotherapy
- Various approaches for first in human dose selection

Rodney Prell, Senior Scientist/Toxicologist, Cancer Immunotherapy Area Lead, **Genentech**

2.00 Afternoon Refreshments & Networking

Establishing Effective Immuno-Oncology Strategies to Maximize the Efficacy of Established and Novel Checkpoint Pathways

Yan Lan
Senior Director, Translational Immunology
EMD Serono

2.30 Enhancing Anti-Tumor Activity with M7824, a Novel Bifunctional Fusion Protein Targeting PD-L1 and TGF-β

- Rationale behind simultaneously targeting PD-L1 and TGF-β using a bifunctional immunotherapeutic
- Enhanced antitumor efficacy and unique immunophenotypic signature of M7824 in preclinical models
- M7824 as a combination partner

Bob Uger
CSO
Trillium Therapeutics

3.00 Targeting the CD47 "Do Not Eat" Signal With TTI-621 (SIRPa-IgG1 Fc)

- Understanding the rationale behind targeting CD47
- Presenting data from clinical studies of the CD47 blocking agent TTI-621 (SIRPa-IgG1 Fc)
- Discussing combination opportunities involving CD47 blockade

Bernard Fox
Providence Cancer Center

3.30 Chair's Closing Remarks

Pre-Conference Workshop Day | Monday, March 19

Morning Workshops

Workshop A

The Role of the Microbiome in Immuno-Oncology Mechanisms & Therapies

9:00am – 12:00pm

The microbiome has a profound effect on immune cell function and inflammation, which is a hallmark of cancer. Yet our knowledge of these underlying mechanisms is just beginning to be translated into cancer therapies.

In this workshop, we will discuss the dynamic nature and inter-individual variation of the microbiome and how this is applicable to precision medicine. The strengths and limitations of high-throughput sequencing of human clinical samples and gnotobiotic mouse models of cancer will both be explored.

Gain insights into:

- The influence of microbiota on the efficacy of checkpoint inhibitors for immunotherapy
- The prospect of developing drugs targeting microbial enzymes as chemotherapy adjuvants to mitigate inflammatory adverse effects
- The role of microbiota in regulation of T cell subsets (e.g., Treg and Th17) and cytokine expression (e.g., IL-10)
- Probiotics and prebiotics: the metabolic capacity of gut microbiota to prevent cancer via anti-inflammatory mechanisms

Workshop leaders:

Scott Bultman
Associate Professor, Genetics
UNC School of Medicine

Lata Jayaraman
Head of Tumor Immunotherapy
Seres Therapeutics

OR

Workshop B

Immunogenicity of Therapeutic Proteins – Considerations for Immune Checkpoint Blocker Therapeutics

9:00am – 12:00pm

Immune checkpoint blockade therapy is emerging as a revolutionary approach to cancer treatment. However, because of the protein origin of many of these therapies, there is a potential for development of unwanted immunogenic responses to the protein therapies that could limit their efficacy and/or also elicit safety consequences in treated patients. In addition, immunogenic responses can occur in preclinical animal models and confound the interpretation of PK, PD and safety study results.

In this workshop we will discuss the causes of unwanted therapeutic protein immunogenicity, how immunogenicity is currently measured and monitored during preclinical and clinical evaluation, clinical use of protein therapeutics, and strategies to predict, mitigate and manage immunogenicity.

Gain insights into:

- Product, patient and treatment-related factors that contribute to development of unwanted immunogenicity and unwanted consequences
- How to determine appropriate assay formats, what are the assay limitations, and how we should interpret results?
- What is currently known about immunogenicity of immune checkpoint inhibitors?
- What strategies are available to predict, mitigate and manage unwanted immunogenicity?
- What are the regulatory expectations for immunogenicity assessment and management in preclinical and clinical studies?

Workshop leader:

Bonnie Rup
Biopharmaceutical Consultant
Bonnie Rup Consulting

Afternoon Workshops

Workshop C

Evaluation Available *In Vivo* Models for the Development of IO Therapeutic Agents

1:00pm – 4:00pm

An unprecedented range of combination approaches are currently under investigation, but without robust preclinical validation backing the mechanism of action of these strategies, many of these studies will fail to reach their clear potential. This interactive workshop will incorporate insights into a range of in vivo modelling approaches, providing you with the valuable tools to enhance your preclinical development.

You'll come away with a comprehensive immuno-oncology preclinical strategy, including insights that will allow you to improve the robustness of your preclinical approach.

Gain insights into:

- The relative advantages of the range of in vivo models available to develop IO therapeutics
- How models can replicate a more natural and translationally relevant tumor microenvironment
- The situations in which syngeneic mice, GEMMs and strategies of immune system humanisation in mice can add most value to preclinical development
- The predictive validity, efficacy and safety of humanized mouse models

Workshop leader:
Barbara Joyce-Shaikh
Associate Principal Scientist
Merck

OR

Workshop D

Investigating Techniques to Discover Neoantigens & the Role They Can Play in Cancer Immunotherapy

1:00pm – 4:00pm

For many, the future of the cancer immunotherapy field lies in personalizing therapeutics to specific mutations to increase their efficacy. Recent findings have placed increasing recognition on the role of neoantigens in this personalization, and it's clear that the analysis of neoantigens will provide crucial insights into the efficacy of cancer immunotherapies.

This workshop will provide an insight into the role of neoantigens in the response to cancer immunotherapy, before providing a detailed insight into techniques to identify neoantigens from patient samples.

Gain insights into:

- The importance of neoantigen analysis in personalizing immunotherapy
- Mass spectrometry approaches used in the detection of neo-epitopes
- The development of personalized vaccines based on the in-depth analysis of tumor antigens

Workshop leader:
Michal Bassani-Sternberg
Director, Immunopeptidomics Unit at Center of Experimental Therapeutics
UNIL/CHUV

"Great meeting, very informative, great to see what other companies are working on in the field of cancer immunotherapy" **Genentech**

WHO WILL YOU MEET?

Seize this opportunity to engage and network with the experts pioneering the immuno-oncology field.

The potential of immuno-oncology is clear, but in order for this potential to be realized, lessons and key insights from the companies who are directly involved in cutting edge development work must be shared and disseminated. ICI Boston's technical and specific focus of means it is an unparalleled opportunity to engage in meaningful discussion with a focused group of experts working in the field.

Interactive sessions built into the main agenda provide extensive opportunities for cross-functional collaboration. Benchmark your progress and critically evaluate your IO development pipeline and combination strategy.

Leave with clear and actionable insights that will successfully enhance your immuno-oncology development.

ATTENDEE COMPANY TYPE

61% Pharma & Biotech
15% Academic
21% Solution Provider
3% Other

ATTENDEE SENIORITY

25% C-Level & VP
56% Director
19% Scientist

*Based on ICI Boston 2017 attendees

PAST ATTENDEES INCLUDE

abbvie, ADURO BIOTECH, AMGEN, Bristol-Myers Squibb, DANA-FARBER CANCER INSTITUTE, Lilly, EMD SERONO, Genentech, janssen, Jounce THERAPEUTICS, THE UNIVERSITY OF TEXAS MD Anderson Cancer Center, MedImmune, MERCK, MOMENTA, Memorial Sloan Kettering 1884, NOVARTIS, Pfizer, SANOFI, Shire

PARTNER WITH US

Are you front of mind when biopharma companies look externally for assistance in the development of immuno-oncology therapeutics?

ICI Boston will bring together senior decision makers from drug developer organizations who are committed to optimizing the development of immuno-oncology therapeutics.

This meeting will offer you unrivalled opportunities to showcase your solutions, generate new business leads and source opportunities for partnerships.

Engage with the key people you need to, in order to stay ahead of the curve and secure your position in the IO space.

To find out more, email **sponsor@hansonwade.com**

> "A very informative meeting with all the major players in the field present"
> **Genscript, Previous ICI Boston Partner**

> "A valuable business and educational opportunity in a rapidly growing field"
> **Immudex, Previous ICI Boston Partner**

PARTNERS

MITRA BIOTECH

Program Partner

Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery. Our phenotypic CANscript platform delivers powerful insight for our biopharma partners. Because CANscript conserves the native tumor microenvironment and delivers 1:1 clinical correlation, it can be used to predict response of an indication to a specific drug (or drug combination), or to better understand MOA of a given compound.

www.mitrabiotech.com

IMMUDEX

Exhibition Partner

Based in Copenhagen, Denmark with North American operations based in Fairfax, Virginia, Immudex manufactures MHC Dextramers, the leading MHC multimer reagent for the detection of antigen-specific T cells. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.

www.immudex.com

BECOME A PARTNER

Mo Langhi
Commercial Director
T. +44 (0)20 3141 8700
E. sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.immune-checkpoint.com/register

Tel: +1 212 537 5898

Email: register@hansonwade.com

1. Establish a robust combination strategy by delving into the details of successful programs
2. Learn about novel approaches and combinations that can take your IO development to the next level
3. Improve your clinical success rate by learning how to stratify and select patients more effectively

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

SECURE YOUR PLACE

Package Details Choose Your Package	Register & Pay By Friday, December 8	Standard Rate
Conference & 2 Workshops	$3697 **(save $500)**	$3997 **(save $200)**
Conference & 1 Workshop	$3098 **(save $400)**	$3398 **(save $100)**
Conference Only	$2499 **(save $300)**	$2799
Workshop Only	$699	

Academics are entitled to 40% off the drug developer prices. Use code "ACA" when registering online.

"Good mix of academic & pharma speakers, overall the conference was a great success."
GSK



VENUE

The Revere Hotel
200 Stuart St, Boston, MA 02116, USA

For further information or assistance, please visit www.reverehotel.com

Code: 9465